Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jun 6;27(3):423–437. doi: 10.1177/0963689717721217

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2017

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Fig. 3. — Effect of acute and chronic 2-(2-(5-methoxy-1H-indol-3-yl)ethyl)-5-methyl-1,3,4-oxadiazole (IQM316) or melatonin administration on hippocampal oxidative phosphorylation (OXPHOS) protein levels. Animals were treated with vehicle (Vhc), IQM316 (IQM), or melatonin (Mel). Quantitative analysis of the effect of acute (A) and chronic (C) administrations on hippocampal OXPHOS protein levels. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used for normalization. Representative Western blots for acute (B) and chronic (D) administrations quantified in A and C, respectively. Acute administration of either IQM316 or melatonin significantly increased subunit B of complex II and complex I subunit (COX I) protein levels but reduced COX IV and ATP-5β. Nonetheless, chronic IQM316 or melatonin administration only increased the protein levels of NDUFB8. Data are mean ± SEM, n = 8 animals per group. *P < 0.05, **P < 0.01, ***P < 0.001, significantly different from vehicle, Bonferroni post hoc test.